Selection of Muscle‑Relaxant Therapies That Preserve Blood Pressure

Agents to Avoid When Blood‑Pressure Stability Is Required

Tizanidine should be avoided because its alpha‑2‑adrenergic agonist activity produces dose‑dependent hypotension. 1
Baclofen carries cardiovascular risk in older adults and may cause dizziness and somnolence, although its hypotensive effect is inconsistent. 4
Benzodiazepines are not recommended for musculoskeletal pain: they offer no advantage over skeletal‑muscle relaxants, have abuse potential, and lack FDA approval for this indication. 7

Methocarbamol, chlorzoxazone, and metaxalone are the safest options regarding cardiovascular stability. 4
Cyclobenzaprine does not lower blood pressure but is associated with anticholinergic effects and sedation; limit use to 7–14 days. 5
Carisoprodol should be avoided because of its abuse potential (metabolizes to meprobamate), despite lacking hypotensive effects. 5

First‑line therapy: methocarbamol or metaxalone for 2–4 days provides modest short‑term pain relief (risk ratio 1.25–1.72 vs. placebo). 8
Adverse‑event profile: all skeletal‑muscle relaxants double the risk of central‑nervous‑system adverse events (RR 2.04), primarily sedation and dizziness. 8
Duration limitation: therapy should not exceed 7–14 days; longer courses have no proven benefit and increase fall risk. 3

First‑line agents: gabapentin or pregabalin are FDA‑approved for neuropathic pain and have stronger supporting evidence than muscle relaxants. 9
Therapeutic trial length: gabapentin requires 5–10 weeks (3–8 weeks titration plus 2 weeks at target dose) to assess efficacy. 3
Renal dosing: renal function must be evaluated before initiating gabapentinoids, with dose adjustments for insufficiency. 3
Side‑effect profile: gabapentinoids cause somnolence, dizziness, and weight gain but do not induce hypotension. 10

Duloxetine (SNRI) or tricyclic antidepressants are evidence‑based options; however, TCAs may cause hypertension, postural hypotension, and arrhythmias, limiting their use. 4
Pregabalin is FDA‑approved for fibromyalgia and provides analgesia without affecting blood pressure. 9
Cyclobenzaprine can be useful for fibromyalgia but should be time‑limited because of anticholinergic burden. 9

Baclofen is the preferred GABA‑B agonist for true spasticity, though it does not treat underlying spinal cord compression. 4
Titration strategy: start with a low dose and increase slowly to minimize dizziness, somnolence, and gastrointestinal symptoms. 5
Discontinuation: taper baclofen gradually to avoid withdrawal seizures and delirium. 5

Avoid concurrent use of muscle relaxants with benzodiazepines or opioids because of a marked increase in sedation and risk of respiratory depression. 3
Combining muscle relaxants with NSAIDs shows inconsistent benefit; four randomized trials found no clear advantage. 7
Older adults: all muscle relaxants raise fall risk; cyclobenzaprine and carisoprodol are especially problematic due to anticholinergic effects and abuse potential. 4
Renal/hepatic failure (anesthesia context): atracurium or cisatracurium are preferred for neuromuscular blockade because they are eliminated independently of organ function. 11

Mechanism: muscle relaxants do not produce true skeletal‑muscle relaxation; their effect is nonspecific CNS depression. 5
Clinical misconception: prescribing muscle relaxants with the expectation of directly relieving muscle spasm is unfounded; their action is via polysynaptic reflex inhibition, not peripheral muscle targeting. 5
Tizanidine contraindication: do not use when blood‑pressure stability is required because of dose‑dependent hypotension. 1
Therapy duration: do not extend muscle‑relaxant treatment beyond 2 weeks; all efficacy trials evaluated only short‑term use (≤14 days), and chronic use increases adverse events without proven benefit. 8
Radicular pain monotherapy: muscle relaxants should not be used alone for chronic radicular pain; gabapentinoids have superior evidence and FDA approval. 3